Advanced Renal Cell Carcinoma
Conditions
Keywords
Renal Cancer
Brief summary
Multicenter, 2-part, multiple-dose study designed to evaluate the safety and effectiveness of weekly administration of panitumumab in subjects with renal carcinoma. Part 1 was initiated in 2001 and will not be presented here. Part 2 was designed to examine a dose of 2.5 mg/kg/wk in 2 cohorts.
Interventions
Sponsors
Amgen
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Inclusion criteria
* Able to comprehend and sign an IRB approved Informed Cosent Form * Male or female 18 years of age or older * Female patients who are post menopausal (no menstrual period for a minimum of six months), surgically sterilized, or are using an oral or implanted contraceptive, double barrier birth control, or an IUD and have a negative serum pregnancy test upon entry into this study; or male patients willing to use contraception upon enrollment into this study * Pathologic diagnosis of renal cell carcinoma by fine needle aspirate or tissue biopsy * Prior nephrectomy * Prior Therapy: 1. Cohort 1 only: Previously received and failed one prior biotherapy, defined as IL-2 therapy or interferon-alpha (alone or in combination); Karnosky score of \> or = 70% 2. Cohort 2 only: No prior therapy except nephrectomy and fall within the Motzer intermediate group with one or two of the risk factors, as defined in teh Study Design section. * Has bi-dimensionally measurable disease * Has tumor tissue available for diagnostics (acceptable: biopsy, nephrectomy tissue, fine needle aspirate, or archived tissue that is formalin fixed and paraffin embedded). In cases when a fresh biopsy can be obtained, the biopsy should be divided into two; one half should be formalin fixed, and the other half frozen. Tumor samples must be received at the central laboratory prior to patient regisration. * Adequate hematologic data, as follows: 1. ANC \> 1.5 x 109/L 2. Platelet count \> 100x 109/L * Adequate renal function, as follows: 1\. Creatinine \< or = 2.2mg/dL * Adequate hepatic function, as follows: 1. Alkaline phosphatase \< or = 3x ULN 2. AST \< or = 3x ULN 3. ALT \< or = 3x ULN 4. Total bilirubin \< or = 1.5x ULN
Exclusion criteria
* Brain metastases * Cohort 1 only: Hypercalcemia (calcium level outside the upper limit of normal; antihypercalcemic treatment is allowed) * Cancer therapy within 30 days of ABX-EGF infusion (hormone therapy is allowed; steroid therapy is only allowed if it is replacement therapy) * Use of any investigational drug within 30 days of ABX-EGF infusion * Prior treatment with any anti-EGFr agents * Left ventricular ejection fraction \< 45%, as measured by MUGA Scan * Myocardial infarction within one year prior to entering the study * Has other cancer that has been active and required treatment within the past 5 years (prior renal cell carcinoma, basal cell carcinoma, or cervical carcinoma in situ are allowed) * Pregnant or breast feeding female; male or female of childbearing potential (defined as: post menarche and is biologically capable of becoming pregnant) unwilling to use birth control (as defined in the inclusion criteria) during and for 1 month following treatment * Known to be HIV positive * History of any chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risks associated with study participation or study drug administration or may interfere with the interpretation of study results * Allergy to the ingredients of the study medication or to Staphylococcus Protein A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 2, Cohort 1: Efficacy: Tumor response rate (CR or PR) measured at 8 weeks | — |
| Part 2, Cohort 1: Safety: Incidence and severity of AEs | — |
| Part 2, Cohort 2: Time to disease progression | — |
Secondary
| Measure | Time frame |
|---|---|
| Part 2, Cohorts 1 & 2: Best overall response rate | — |
| Part 2, Cohorts 1 & 2: Tumor response rate at Weeks 15, 23, 31, and 39 | — |
| Part 2, Cohorts 1 & 2: Duration of response | — |
| Part 2, Cohort 1: Time to disease progression | — |
| Part 2, Cohorts 1 & 2: Time to CR | — |
| Part 2, Cohorts 1 & 2: Time to response (PR or CR) | — |
| Part 2, Cohorts 1 & 2: Percent of patients with progressive disease (measured at 8 weeks following initiation of panitumumab treatment) | — |
| Part 2, Cohorts 1 & 2: Survival time | — |
| Part 2, Cohorts 1 & 2: PFS | — |
Outcome results
None listed